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INTRODUCTION 
Cataract surgery is one of the most common ocular 
surgeries. The studies done in different regions have 
reported prevalence of the Cataract 50% and 75% in the 
age groups 65-74 and at the age above 75 years 
respectively.
1,2
 
The most common complication of cataract surgery is 
posterior capsule opacity (PCO), which results from 
normal posterior capsule (28 percent over five years). 
This capsule opacification is caused by the lens epithelial 
cells that have survived after the loss of the nucleus and 
cortex, and have proliferated.
1-3
 Fortunately, PCO 
responds to neodymium YAG laser posterior 
capsulotomy. Transient elevated IOP can occur in a 
significant number of patients following neodymium 
YAG laser posterior capsulotomy that requires 
prophylactic treatment with intraocular pressure (IOP) 
reducingdrugs, and in some patients, postoperative IOP 
monitoring.
1,2
 
Currently, for this complication prevention, various 
drugs, including acetazolamide and Timololare has been 
used that these drugs have less side effects and need to be 
consumed many times by patients. Both brimonidine and 
Xalatan are of new drugs used for treating glaucoma, that 
due to their high efficacy and lower side effects are 
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highly prescribed by physicians and many studies in 
many countries have examined the effectiveness of these 
drugs and have found satisfying results. And now, 
according to these studies, brimonidine is administered 
before YAG laser surgery in most countries. The aim of 
this study was to compare the effectiveness of 
Brimonidine 0.2% or Xalatan 0.005% (Latanoprost) in 
preventing the IOP spikes after YAG laser capsulotomy. 
METHODS 
This is a randomized, double-blind clinical trial study that 
has been done on 100 patients who were candidate for 
undergoing YAG laser capsulotomy in ophthalmology 
clinic of Alavi Hospital. The patients were randomly 
divided into two groups of 50 patients. One group 
received brimonidine 0.2% one hour before surgery, and 
the other group received Xalatan 0.005% in the night 
before laser surgery.  
Inclusion criteria  
Inclusion criteria were having the history of cataract 
surgery with posterior capsular opacification and being a 
candidate for undergoing YAG laser capsulotomy.  
Exclusion criteria  
Exclusion criteria were as follows:  
1. The history of previous glaucoma,  
2. The history of consumption of anti-glaucoma 
medications,  
3. Severe adhesion of lens to surrounding tissues,  
4. The history of uveitis,  
5. The age under 21 years,  
6. Unstable cardiovascular disease,  
7. Being pregnant or lactating. 
The same ophthalmologist (the researcher) examined all 
the patients, measured their IOP (before and after 
surgery), and performed YAG laser posterior 
capsulotomy on them. 
The YAG laser capsulotomy was performed at 9 am, and 
then in the specified intervals (Seven times) their 
intraocular pressure was measured and recorded. 
1. Just before surgery,  
2. One hour after surgery,  
3. Two hours after surgery, 
4. Three hours after surgery,  
5. 24 hours after surgery,  
6. Three days after surgery, 
7. A week after surgery. 
All patients received Betamethasone eye drops every 6 
hours for a week after surgery. The patients whose IOP 
after surgery was above 40 mm Hg received other 
medicines in addition to these drugs, in order fortheir IOP 
to reduce. To collect data, a checklist was completed for 
each patient. The used drugs did not have major side 
effects, and the patients after signing the informed 
consent were included in the study. This study was 
approved by the ethics committee of the Ardabil Medical 
University. In both groups the patients' IOP was 
measured in baseline, 1, 2, 3, 24 hours, 3 days and one 
week after surgery. The gathered data were analyzed 
using statistical methods in SPSS. 
RESULTS 
The average age of patients was 67.3 years in the 
brimonidine group and 61.4 years in the Xalatan group. 
The average of used laser energy was 217 mJ in the 
brimonidine group and 268.2 mJ in Xalatan group. The 
mean IOP before surgery was 15.30±3 in the brimonidine 
which was similar to Xalatan Gorup with 14.34±3.7. The 
mean IOP was 13.8±4.8 one hour after surgery in the 
brimonidine group, and 15.44±6.8 in the Xalatan group, 
and the difference between two groups was not 
statistically significant (Figure 1). 
 
Figure 1: Mean of IOP in two groups in various times. 
There was a significant change in IOP between two 
groups one hour after surgery, but the changes in IOP rate 
in other times not statistically significant between two 
groups (Table 1). 
The type of cataract surgery in both groups in 
tobrimonidine and Xalatan with 70% and 60% was 
phacosection, respectively (Table 2). 
The greatest degree of visual improvement in both groups 
of brimonidine and Xalatan, with 46% and 38%, 
respectively, was “2 lines or more in Snellen chart”, and 
there was no statistically significant difference between 
the two groups in terms of visual improvement after 
surgery )Table 3). 
DISCUSSION 
Studies on the use of drugs brimonidine 0.2% or 
latanoprost (Xalatan) 005% as anti-glaucoma eye drops 
for preventing IOP spikes following YAG laser 
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capsulotomy showed that the impact of these drops in 
preventing IOP elevation was similar to other drugs.
3-15
 
 
Table 1: Compare the IOP changes between two groups in various times. 
Times  
IOP changes 
group 
Decrease 
from 
baseline 
No 
change 
Increase 
less than 5 
mmhg 
Increase 
more than 
5 mmhg 
Increase 
more than 
10 mmhg 
p-value 
1 hour after surgery  
Brimonidine 33(66) 3(6) 11(22) 3(6) 0 
0.038 
Xalatan 20(40) 8(16) 13(26) 5(10) 4(8) 
2hour after surgery 
Brimonidine 27(54) 4(8) 11(22) 4(8) 4(8) 
0.7 
Xalatan 21(42) 7(14) 14(28) 3(6) 5(10) 
3 hour after surgery 
Brimonidine 25(50) 1(2) 11(22) 7(14) 6(12) 
0.3 
Xalatan 25(50) 4(8) 13(26) 2(4) 6(12) 
24 hour after surgery 
Brimonidine 23(46) 5(10) 13(26) 3(6) 6(12) 
0.6 
Xalatan 24(48) 6(12) 13(26) 5(10) 2(4) 
3 days after surgery 
Brimonidine 24(48) 3(6) 14(28) 4(8) 5(10) 
0.43 
Xalatan 19(38) 6(12) 16(32) 7(14) 2(4) 
one week after surgery 
Brimonidine 19(38) 3(6) 22(44) 6(12) 0 
0.66 
Xalatan 16(32) 6(12) 20(40) 7(14) 1(2) 
Table 2: Type of cataract surgery in two groups. 
Type of surgery 
groups 
Phacoemulsification Phacosection Extra-capsular cataract extraction Total  
N % N % N % N % 
Brimonidine 10 20 35 70 5 10 50 100 
Xalatan 16 32 30 60 4 8 50 100 
Table 3: The degree of improvement in vision after YAG in two groups. 
Degree 
improvement 
groups  
No 
change 
From 
H.M to 
F.C 
From F.C 
to CLEAR 
F.C  
From F.C 
to Snellen 
chart 
One degree 
improvement in 
Snellen chart 
two degree or more 
improvement in 
Snellen chart 
p-
value 
N % N % N % N % N % N % 
Brimonidine 8 16 0 0 5 10 9 18 5 10 23 46 
0.44 
Xalatan 6 12 4 8 5 10 10 20 6 12 19 38 
 
Teresa, Nancy and Unal in their study, showed that the 
use of brimonidine 0.15% before surgery is comparable 
to the efficacy and safeness of apraclonidine 0.5% and 
0.1% in preventing IOP elevation after laser anterior 
segment capsulotomy.
5,6,16
 
Seong et al in a study identified the positive influence of 
brimonidine 0.2% as an eye drop in preventing IOP 
elevation after YAG laser capsulotomy.
7
 
Yeom and et al in a study used two different 
concentrations of brimonidine (0.2% and 0.15%) and 
showed their high effectiveness in preventing IOP rise 
after YAG laser capsulotomy and also they suggest that 
both drugs had a similar impact on preventing IOP 
increase.
4
 
Negar and et al in a study showed that in patients with 
high IOP and wide-angle glaucoma, latanoprost is more 
effective in IOP control than laser trabeculoplasty.
11
 
Robert and et al in a study showed that the effect of 
latanoprost alone is equal to the combined effect of 
Dorzolamide / Timolol in lowering IOP.
3
 
Catherine and et al in a study demonstrated that 
Latanoprost decreases the IOP elevation in patients after 
YAG laser iridotomy (LI).
12
 In the present study, like 
other studies, both medications were proved to be 
effective in controlling IOP after surgery. 
Considering the results obtained from two groups, no 
significant difference was seen between groups regarding 
the mean pressurein the intervals of measurement. But in 
terms of peak rise in IOP, the greatest increase in the 
brominidine group (16 patients) was observed 24 hours 
after surgery, and in the Xalatan group (12 patients) three 
days after surgery. However, this difference was no 
statistically significant. The groups varied from each 
other significantly concerning IOP change one hour after 
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surgery, while it was not significant in other 
measurements carried out at other times. 
As the patients in this study underwent YAG laser 
capsulotomy when the administered drugs were in their 
peak effect, that is, Bromindine 0.2% one hour before 
surgery (with a peak effect 2 hours after dosing), and 
Xalatan 0.005% the night before surgery at 10 p.m. (with 
a peak effect 10-14 hours after dosing), and since the 
previously done studies haven't taken Xalatan as such, 
they obtained results and statistics in this study may yield 
more accurate outcomes. 
Moreover, in as much as the risk of IOP elevation after 
surgery is until 3 days after the surgery, in this study, IOP 
was measured 1 hour, 2 hours, 3 hours, 24 hours, 3 days, 
and one week after surgery. By so doing, it can be 
claimed that the present study can be more accurate in 
IOP monitoring after surgery than other studies 
undertaken in this area to date. 
Haydar et al, examined the effect of Latanoprost 0.005% 
and 0.2% brimonidine in preventing IOP elevation after 
phacoemulsification and intraocular lens implantation 
surgery, and found the efficacy of two eye drops was 
similar.
8
 
Novak-Laus et al, in their study found that latanoprost or 
brominidine are more effective than pilocarpine in 
reducing IOP following YAG laser iridotomy.
9
 
William et al. also compared the effect of brimonidine 
0.2% and Unoprostone 0.15% (Another prostaglandin 
analog) on IOP reduction and found that consuming 
brimonidine twice a day has greater effect on reducing 
peak IOP than Unoprostone.
14
 
CONCLUSION 
Based on the results of this study, it can be said that the 
prophylactic use of a single dose of latanoprost 0.005% 
before YAG posterior laser capsulotomy is similar to use 
of brimonidine 0.2%, and is effective in preventing IOP 
rise. Because elevated IOP after YAG posterior laser 
capsulotomy occurs in most patients, and requires drug 
treatment after surgery , it is suggested that a single dose 
of brimonidine or latanoprost before YAG laser 
capsulotomy be used as a prophylactic medicine, so that 
there wouldn't be need for consuming multiple drugs after 
surgery. 
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